RTP Mobile Logo
CNS Cancer Update, Issue 2, 2010
Released December 2010

Featuring interviews with Drs Timothy F Cloughesy, Patrick Y Wen, Jon D Weingart and David M Peereboom. (Text and Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY

    Brain tumors are a diverse group of neoplasms arising from different cells within the central nervous system (CNS) or from systemic tumors that have metastasized to the CNS. Primary brain tumors include a number of histologic types with markedly different tumor growth rates and are divided into anaplastic gliomas (anaplastic astrocytoma, anaplastic oligodendroglioma and anaplastic oligoastrocytoma) and glioblastoma multiforme (GBM) based on their histopathologic features. Despite treatment, the median survival for anaplastic oligodendroglioma is two to three years, and patients with GBM can succumb to their disease within a year of the onset. Thus, clinical education regarding standard and evolving best-practice therapeutic management of these neoplasms is essential to improving patient outcomes. To bridge the gap between research and patient care, this issue of CNS Cancer Update features one-on-one discussions with leading neuro-oncologists and neurosurgeons. By providing information on the latest research developments in the context of expert perspectives, this activity assists medical oncologists with the formulation of state-of-the-art clinical management strategies, which in turn facilitates optimal patient care.

    LEARNING OBJECTIVES

    • Identify strategies to distinguish between true disease progression and radiographic pseudoprogression in patients with glioma who have undergone chemoradiation therapy.
    • Apply advances in imaging and neuropathology to diagnose, prognosticate and measure response to therapy for patients with CNS tumors.
    • Use the results of new clinical studies for CNS tumors to improve patient outcomes.
    • Recall the results of existing and emerging research on interstitial chemotherapy for patients with Grade III or IV gliomas.
    • Integrate palliative management initiatives to improve quality of life for patients with brain tumors.
    • Develop evidence-based clinical management strategies for recurrent or progressive GBM.
    • Counsel appropriately selected patients about the availability of ongoing clinical trials in which they may be eligible to participate.

    ACCREDITATION STATEMENT

    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT

    Research To Practice designates this educational activity for a maximum of 3 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY


    This CME activity contains both audio and print components. To receive credit, the participant should listen to the audio MP3s, read the text portion and complete the Post-test and Educational Assessment and Credit Form located on our website at CME.ResearchToPractice.com. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES


    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY
    Dr Weingart had no real or apparent conflicts of interest to disclose. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr CloughesyAdvisory Committee: AstraZeneca Pharmaceuticals LP, Genentech BioOncology, Roche Laboratories Inc; Consulting Agreements: Genentech BioOncology, Roche Laboratories Inc; Speakers Bureau: Merck and Company Inc. Dr WenPaid Research: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Schering-Plough Corporation. Dr PeereboomHonorarium: Schering-Plough Corporation.

    EDITOR
    Dr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: Abraxis BioScience Inc, a wholly owned subsidiary of Celgene Corporation, Allos Therapeutics, Amgen Inc, AstraZeneca Pharmaceuticals LP, Aureon Laboratories Inc, Bayer HealthCare Pharmaceuticals/Onyx Pharmaceuticals Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Cephalon Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Genentech BioOncology, Genomic Health Inc, Lilly USA LLC, Millennium Pharmaceuticals Inc, Myriad Genetics Inc, Novartis Pharmaceuticals Corporation, OSI Oncology, Sanofi-Aventis and Spectrum Pharmaceuticals Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS
    — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.


    This program is supported by educational grants from AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc and Genentech BioOncology.


    Hardware/Software Requirements:

    An Internet connection that is at least 28.8 Kbps
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 6.x or newer, Firefox 2.x or newer, or Safari 2.x or newer
    Macromedia Flash plug-in 6.0 or greater
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: December 2010
    Expiration date: December 2011

Acknowledge and close

CNS Cancer Update, Issue 2, 2010
Released December 2010

Featuring interviews with Drs Timothy F Cloughesy, Patrick Y Wen, Jon D Weingart and David M Peereboom. (Text and Audio Content)